International Journal of Hematology

, Volume 93, Issue 1, pp 36–46 | Cite as

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial

  • Yuzuru KanakuraEmail author
  • Kazuma Ohyashiki
  • Tsutomu Shichishima
  • Shinichiro Okamoto
  • Kiyoshi Ando
  • Haruhiko Ninomiya
  • Tatsuya Kawaguchi
  • Shinji Nakao
  • Hideki Nakakuma
  • Jun-ichi Nishimura
  • Taroh Kinoshita
  • Camille L. Bedrosian
  • Marye Ellen Valentine
  • Gus Khursigara
  • Keiya Ozawa
  • Mitsuhiro Omine
Original Article


Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive and life-threatening disease characterized by complement-mediated chronic hemolysis, resulting in serious life-threatening complications and early mortality. Eculizumab, a humanized anti-C5 monoclonal antibody that inhibits terminal complement activation, has been shown to reduce hemolysis in PNH patients. The pivotal open-label, 12-week phase II registration study (AEGIS) was designed to evaluate the efficacy and safety of eculizumab in Japanese patients with PNH. This trial achieved its primary endpoint of reducing intravascular hemolysis with high statistical significance. Twenty-seven of the 29 patients responded to eculizumab treatment, resulting in an 87% reduction in hemolysis (P < 0.0001) and subsequent improvement in anemia (P = 0.0003) despite reduction in transfusion requirements (P = 0.006). Fatigue and dyspnea significantly improved within 1–2 weeks of eculizumab treatment and the improvement was independent of changes in hemoglobin. Chronic kidney disease (CKD) was common (66%) and eculizumab treatment improved CKD in 41% of patients at 12 weeks (P < 0.001). Elevated thrombotic risk was evident in Japanese PNH patients and eculizumab treatment normalized d-dimer levels in 45% of patients with elevated d-dimers at baseline (P < 0.001). The AEGIS results demonstrate that eculizumab is effective, safe and well tolerated in Japanese patients with PNH.


Paroxysmal nocturnal hemoglobinuria Complement-inactivating agents Hemolysis Eculizumab Hematopoietic stem cell 


  1. 1.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.Google Scholar
  2. 2.
    Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol. 2005;252:1379–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13:110–7.PubMedGoogle Scholar
  4. 4.
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro CC, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. 4th ed. Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.Google Scholar
  6. 6.
    Cella D, et al. The FACIT-Fatigue Scale: description, reliability and validity. Evanston, IL: Center on Outcomes, Research and Education; 2003. p. 1–18.Google Scholar
  7. 7.
    Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–38.CrossRefPubMedGoogle Scholar
  8. 8.
    Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia. 2000;20:437–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57:83–9.PubMedGoogle Scholar
  10. 10.
    de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY, Socie G. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–106.CrossRefPubMedGoogle Scholar
  11. 11.
    Delles C, Klingbeil AU, Schneider MP, Handrock R, Schaufele T, Schmieder RE. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transpl. 2004;19:1392–7.CrossRefGoogle Scholar
  12. 12.
    Gabbai FB. Effects of nitric oxide synthase blockers on renal function. Nephrol Dial Transpl. 2001;16(Suppl 1):10–3.Google Scholar
  13. 13.
    Helley D, de Latour RP, Porcher R, Arrais C, Fauroux I, Matheron J, Duval A, Shved JF, Fischer AM, Socie G. Eculizumab inhibits clot generation and endothelial dysfunction in patients with paroxysmal nocturnal haemoglobinuria. Haematologica. 2010;95:574–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Hill A, Muus P, Duhrsen U, Socie G, Risitano A, De Paz R, Van den Neste E, Zanella A, Lai J, Hillmen P, Rother R, Cella D. Improvement in fatigue with eculizumab treatment of patients with PNH occurs independent of changes in anemia. EHA. 2008.Google Scholar
  15. 15.
    Hill A, Rother RP, Wang X, Morris SM, Quinn-Senger K, Richards SJ, Bessler M, Kelly R, Hillmen P, Gladwin M. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149:414–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Hill A, Reid SA, Rother RP, Gladwin MT, Collinson PO, Gaze DC, Lowe A, Guthrie A, Sivananthan MU, Hillmen P. High definition contrast-enhanced mr imaging in paroxysmal nocturnal hemoglobinuria (PNH) suggests a high frequency of subclinical thrombosis. Blood. 2006;108(11) (Abstract 979).Google Scholar
  17. 17.
    Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, Mojcik CF, Rother RP. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Rother R, Khursigara G, Fu CL, Browne P, Rosse W. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553–9.Google Scholar
  20. 20.
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian C, Valentine ME, Ozawa K, Omine M. Chronic renal insufficiency in japanese patients with paroxysmal nocturnal hemoglobinuria (PNH): improvement with eculizumab treatment in the long-term follow-up of the AEGIS Study. Blood. 2009;114 (Abstract 1980).Google Scholar
  24. 24.
    Muus P, Risitano A, Castro-Malaspina H, Jones C, Fuller S, Socie G. Clinical impact of unregulated terminal complement activity in never-transfused patients with paroxysmal nocturnal hemoglobinuria. Blood. 2009;114 (Abstract).Google Scholar
  25. 25.
    Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, Haggard JJ, Croatt AJ, Payne WD, Alam J. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int. 2001;59:106–17.CrossRefPubMedGoogle Scholar
  26. 26.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. 2002.Google Scholar
  27. 27.
    Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, Decastro CM, Hall S, Kanamaru A, Sullivan KM, Mizoguchi H, Omine M, Kinoshita T, Rosse WF. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.CrossRefGoogle Scholar
  28. 28.
    Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socie G. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.CrossRefPubMedGoogle Scholar
  29. 29.
    Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2007;35:523–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995;96:1564–72.CrossRefPubMedGoogle Scholar
  31. 31.
    Rosse W. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, editor. Hematology: basic principles and practice. 3rd ed. Philadelphia: Churchill Livingstone, Inc. 2000.Google Scholar
  32. 32.
    Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.CrossRefPubMedGoogle Scholar
  33. 33.
    Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE. Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens. 2008;26:110–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Schneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambaryan S, Wanner C, Schmidt HH, Galle J. l-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney Int. 2003;64:216–25.CrossRefPubMedGoogle Scholar
  36. 36.
    Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Socie G, Hillmen P, Muus P, Schubert J, Duhrsen U, Risitano AM, Rother RP, Brodsky RA, Szer J. Sustained improvements in transfusion requirements, fatigue and thrombosis with eculizumab treatment in paroxysmal nocturnal hemoglobinuria. ASH Annu Meet Abstr. 2007;110:3672.Google Scholar
  38. 38.
    Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–11.CrossRefPubMedGoogle Scholar
  39. 39.
    Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–401.CrossRefPubMedGoogle Scholar
  40. 40.
    Weitz IC, Ghods M, Rochanda L, Prazavi P, Zwicker J, Furie B, Liebman H. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH. ASH Annu Meet Abstr. 2008;112:407.Google Scholar
  41. 41.
    Yamada N, Miyata T, Maeda K, Kitani T, Takeda J, Kinoshita T. Somatic mutations of the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood. 1995;85:885–92.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Yuzuru Kanakura
    • 1
    Email author
  • Kazuma Ohyashiki
    • 2
  • Tsutomu Shichishima
    • 3
  • Shinichiro Okamoto
    • 4
  • Kiyoshi Ando
    • 5
  • Haruhiko Ninomiya
    • 6
  • Tatsuya Kawaguchi
    • 7
  • Shinji Nakao
    • 8
  • Hideki Nakakuma
    • 9
  • Jun-ichi Nishimura
    • 1
  • Taroh Kinoshita
    • 10
  • Camille L. Bedrosian
    • 11
  • Marye Ellen Valentine
    • 11
  • Gus Khursigara
    • 11
  • Keiya Ozawa
    • 12
  • Mitsuhiro Omine
    • 13
  1. 1.Department of Hematology and OncologyOsaka University HospitalSuitaJapan
  2. 2.Tokyo Medical University HospitalTokyoJapan
  3. 3.Fukushima Medical UniversityFukushimaJapan
  4. 4.Division of HematologyKeio University School of MedicineTokyoJapan
  5. 5.Department of Hematology and OncologyTokai UniversityIseharaJapan
  6. 6.University of TsukubaTsukubaJapan
  7. 7.Kumamoto UniversityKumamotoJapan
  8. 8.Cellular Transplantation BiologyKanazawa UniversityKanazawaJapan
  9. 9.Department of Hematology/OncologyWakayama Medical UniversityWakayamaJapan
  10. 10.Research Institute for Microbial DiseasesOsaka University HospitalSuitaJapan
  11. 11.Alexion PharmaceuticalsCheshireUSA
  12. 12.Jichi Medical University HospitalTochigiJapan
  13. 13.Showa University Fujigaoka HospitalYokohamaJapan

Personalised recommendations